Disease Management : Separating Fact From Fantasy. Conference. Tucson, Arizona (USA), 1996/01/23.
This paper provides an overview of how one pharmacy benefits manager, Medlmpact Pharmaceutical Management, Inc. (San Diego, California), approaches its disease management (DM) program for asthma.
This group's experience with DM counters the common but fallacious belief that reduction of component costs leads to reduction of total expenditures.
In fact, greater expenditures on certain components (in particular, drug therapies and preventive and follow-up visits to physicians) can result in greatly reduced overall expenditures by reducing hospitalizations and emergency department treatments for asthmatic patients.
The program addresses four essential components of DM : physician intervention, patient empowerment, health risk management, and pharmaceutical care.
For each of these areas, careful statistical analysis, effective education, and integrated management can help improve patient care while reducing overall costs.
Mots-clés Pascal : Antiasthmatique, Chimiothérapie, Traitement, Asthme, Choix, Qualité, Coût, Etude cas, Homme, Economie santé, Etats Unis, Amérique du Nord, Amérique, Appareil respiratoire pathologie, Bronchopneumopathie obstructive
Mots-clés Pascal anglais : Antiasthma agent, Chemotherapy, Treatment, Asthma, Choice, Quality, Costs, Case study, Human, Health economy, United States, North America, America, Respiratory disease, Obstructive pulmonary disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0159996
Code Inist : 002B02D. Création : 21/05/1997.